Institutional portfolio tracker

Viking Global Portfolio & AI Predictions

Explore Viking Global's latest validated 13F portfolio and Hallucination Yield AI forecasts for covered positions.

Form 13F reports holdings as of 2026-03-31 and was filed on 2026-05-15. It is delayed, can omit confidential positions, and is not the manager's current portfolio or fund NAV. Options show reported underlying value—not premium, net exposure, or investment intent.

Disclosed long book

$34.90 billion

Long positions

77

Calls / puts

0 / 0

Top 5 concentration

21.0%

Longs with AI data

22 / 77

Average AI 1Y

+16.0%

Official SEC filing ↗Exact filing eventPermanent quarter pageJSONDownload CSV

Monitored between quarterly reports

Beneficial-ownership disclosures

Schedules 13D and 13G can reveal a significant ownership event after a quarter closes. They are shown as a separate event timeline and never folded back into the 2026-03-31 Form 13F portfolio.

BridgeBio Pharma, Inc.

SCHEDULE 13D/APost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of July 9, 2026: 9,792,219 shares or share-equivalents representing 5% of the reported class. It was filed on July 10, 2026.

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Common Stock, par value $0.001 per share (the "Common Stock"), of BridgeBio Pharma, Inc. (the "Issuer"). The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101. All share percentage calculations in this Amendment No. 12 to the Schedule 13D are based on 196,036,786 shares of Common Stock of the Issuer outstanding as of May 31, 2026, as reported in exhibit 10.1 to the Issuer's current report on Form 8-K filed with the

Official SEC disclosure ↗

STANDARD BIOTOOLS INC.

SCHEDULE 13DPost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 6, 2026: 58,651,170 shares or share-equivalents representing 15% of the reported class. It was filed on June 12, 2026.

All share percentage calculations in this Schedule 13D are based on 390,368,119 shares of Common Stock outstanding as of May 4, 2026, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026.

Official SEC disclosure ↗

Artiva Biotherapeutics, Inc.

SCHEDULE 13GPost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of May 11, 2026: 2,604,166 shares or share-equivalents representing 5.4% of the reported class. It was filed on May 18, 2026.

See Item 4

Official SEC disclosure ↗

Inhibrx Biosciences, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 1,461,633 shares or share-equivalents representing 9.99% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Oruka Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 2,666,690 shares or share-equivalents representing 5.3% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

PepGen Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,482,434 shares or share-equivalents representing 5.03% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Veradermics, Inc

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 1,690,555 shares or share-equivalents representing 4.5% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Pharvaris N.V.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,653,310 shares or share-equivalents representing 5.6% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Adaptive Biotechnologies Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 29,993,708 shares or share-equivalents representing 18.8% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Sionna Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,195,181 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Oric Pharmaceuticals, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 8,264,607 shares or share-equivalents representing 7.8% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

TIC Solutions, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 35,824,562 shares or share-equivalents representing 16.2% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

STANDARD BIOTOOLS INC.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 58,651,170 shares or share-equivalents representing 15% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Fortive Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 22,479,388 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Rallybio Corporation

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 528,954 shares or share-equivalents representing 9.99% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Chewy, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 0 shares or share-equivalents representing 0% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Ginkgo Bioworks Holdings, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,577,128 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Altimmune, Inc.

SCHEDULE 13GPost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 24, 2026: 13,400,000 shares or share-equivalents representing 6.7% of the reported class. It was filed on May 1, 2026.

See Item 4

Official SEC disclosure ↗

LENNOX INTERNATIONAL INC

SCHEDULE 13GPost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 15, 2026: 1,815,350 shares or share-equivalents representing 5.2% of the reported class. It was filed on April 22, 2026.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 11,842,434 shares or share-equivalents representing 6.1% of the reported class. It was filed on April 2, 2026.

All share percentage calculations in this Amendment No. 11 to the Schedule 13D are based on 193,862,871 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of February 12, 2026, as reported in the Issuer's annual report on Form 10-K filed with the Securities and Exchange Commission (the "Commission") on February 24, 2026.

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 12, 2026: 13,026,367 shares or share-equivalents representing 6.8% of the reported class. It was filed on February 17, 2026.

All share percentage calculations in this Amendment No. 10 to the Schedule 13D are based on the difference between (i) 192,708,813 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of October 21, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on October 29, 2025, and (ii) 1,081,825 shares of Common Stock that the Issuer repurchased on January 21, 2026, as reported in the Issuer's current report on Form 8-K filed with the Commission on January 21, 2026.

Official SEC disclosure ↗

Rallybio Corporation

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 4,222,969 shares or share-equivalents representing 9.99% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

Inhibrx Biosciences, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 1,454,608 shares or share-equivalents representing 9.99% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

Primo Brands Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 0 shares or share-equivalents representing 0% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

SAIA INC

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 1,088,582 shares or share-equivalents representing 4.1% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

NewAmsterdam Pharma Co N.V.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 4,203,567 shares or share-equivalents representing 3.7% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

Veradermics, Inc

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 5, 2026: 2,151,493 shares or share-equivalents representing 5.8% of the reported class. It was filed on February 12, 2026.

See Item 4

Official SEC disclosure ↗

REGAL REXNORD CORP

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 6, 2026: 3,301,545 shares or share-equivalents representing 4.97% of the reported class. It was filed on January 13, 2026.

See Item 4

Official SEC disclosure ↗

Chewy, Inc.

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 18, 2025: 13,536,645 shares or share-equivalents representing 5.7% of the reported class. It was filed on December 30, 2025.

See Item 4

Official SEC disclosure ↗

Trevi Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 5,128,875 shares or share-equivalents representing 4.2% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

Roivant Sciences Ltd.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 23,594,831 shares or share-equivalents representing 3.4% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

REGAL REXNORD CORP

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 3,123,262 shares or share-equivalents representing 4.7% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

BIOMARIN PHARMACEUTICAL INC

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 8,322,179 shares or share-equivalents representing 4.3% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

Fortive Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 20,483,680 shares or share-equivalents representing 6.4% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of November 14, 2025: 15,893,934 shares or share-equivalents representing 8.2% of the reported class. It was filed on November 14, 2025.

All share percentage calculations in this Amendment No. 9 to the Schedule 13D are based on 192,708,813 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of October 21, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on October 29, 2025.

Official SEC disclosure ↗

PepGen Inc.

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 26, 2025: 3,482,434 shares or share-equivalents representing 5.1% of the reported class. It was filed on October 3, 2025.

See Item 4

Official SEC disclosure ↗

Oruka Therapeutics, Inc.

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 17, 2025: 2,666,690 shares or share-equivalents representing 5.5% of the reported class. It was filed on September 24, 2025.

See Item 4

Official SEC disclosure ↗

SAIA INC

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 3, 2025: 1,337,356 shares or share-equivalents representing 5.02% of the reported class. It was filed on September 10, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of August 14, 2025: 17,780,183 shares or share-equivalents representing 9.3% of the reported class. It was filed on August 14, 2025.

All share percentage calculations in this Amendment No. 8 to the Schedule 13D are based on 191,168,504 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of July 29, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on August 5, 2025.

Official SEC disclosure ↗

Trevi Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 7,505,694 shares or share-equivalents representing 5.9% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

APi Group Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 11,537,518 shares or share-equivalents representing 2.8% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

Oric Pharmaceuticals, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 8,729,345 shares or share-equivalents representing 9.99% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

REGAL REXNORD CORP

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 3,430,128 shares or share-equivalents representing 5.2% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

BIOMARIN PHARMACEUTICAL INC

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 12,288,611 shares or share-equivalents representing 6.4% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

Roivant Sciences Ltd.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 34,237,779 shares or share-equivalents representing 5.02% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

Fortive Corp

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of July 17, 2025: 17,049,178 shares or share-equivalents representing 5.02% of the reported class. It was filed on July 24, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 27, 2025: 18,602,920 shares or share-equivalents representing 9.8% of the reported class. It was filed on July 1, 2025.

All share percentage calculations in this Amendment No. 7 to the Schedule 13D are based on 189,880,720 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of April 22, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on April 29, 2025.

Official SEC disclosure ↗

Primo Brands Corp

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 11, 2025: 19,602,116 shares or share-equivalents representing 5.3% of the reported class. It was filed on June 18, 2025.

See Item 4

Official SEC disclosure ↗

Roivant Sciences Ltd.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 46,013,752 shares or share-equivalents representing 6.4% of the reported class. It was filed on May 15, 2025.

See Item 4

Official SEC disclosure ↗

Oric Pharmaceuticals, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 6,572,700 shares or share-equivalents representing 9.2% of the reported class. It was filed on May 15, 2025.

See Item 4

Official SEC disclosure ↗

Trevi Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 9,190,486 shares or share-equivalents representing 8.7% of the reported class. It was filed on May 15, 2025.

See Item 4

Official SEC disclosure ↗

ACUREN CORP

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 34,360,000 shares or share-equivalents representing 28.3% of the reported class. It was filed on May 15, 2025.

See Item 4

Official SEC disclosure ↗

REGAL REXNORD CORP

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 11, 2025: 3,546,112 shares or share-equivalents representing 5.3% of the reported class. It was filed on April 18, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 31, 2025: 22,055,375 shares or share-equivalents representing 11.7% of the reported class. It was filed on March 12, 2025.

All share percentage calculations in this Amendment No. 6 to the Schedule 13D are based on 188,989,802 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024.

Official SEC disclosure ↗

Cazoo Group Ltd

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 1, 2024: 2,142,728 shares or share-equivalents representing 43.8% of the reported class. It was filed on March 12, 2025.

All share percentage calculations in this Amendment No. 13 to the Schedule 13D are based on 4,891,002 Ordinary Shares (as defined herein) expected to be outstanding after giving effect to each of the December 2023 Reverse Stock Split (as defined in Amendment No. 12) and the issuance of the New Shares (as defined in Amendment No. 12), as reported in the Issuer's current report on Form 6-K filed with the U.S. Securities and Exchange Commission (the "Commission") on December 7, 2023.

Official SEC disclosure ↗

Sionna Therapeutics, Inc.

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 10, 2025: 2,952,754 shares or share-equivalents representing 6.7% of the reported class. It was filed on February 14, 2025.

See Item 4

Official SEC disclosure ↗

Longboard Pharmaceuticals, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 0 shares or share-equivalents representing 0% of the reported class. It was filed on February 14, 2025.

See Item 4

Official SEC disclosure ↗

NewAmsterdam Pharma Co N.V.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 6,978,534 shares or share-equivalents representing 6.5% of the reported class. It was filed on February 14, 2025.

See Item 4

Official SEC disclosure ↗

APi Group Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 21,537,518 shares or share-equivalents representing 7.8% of the reported class. It was filed on February 14, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 31, 2025: 22,055,375 shares or share-equivalents representing 11.7% of the reported class. It was filed on January 31, 2025.

All share percentage calculations in this Amendment No. 5 to the Schedule 13D are based on 188,989,802 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024.

Official SEC disclosure ↗

13F filing comparison

Quarter-over-quarter changes

2025-12-31 to 2026-03-31

Newly reported

21

No longer reported

20

Increased

25

Reduced

21

Newly reported this quarter

Present now and absent from the immediately preceding comparable filing.

PositionKindSharesValue

APPLE INC

APPLE INC

LONG3,593,057$911.9 million

FDX

FEDEX CORP

LONG1,932,165$688.2 million

META

META PLATFORMS INC

LONG1,062,575$607.9 million

ATI INC

ATI INC

LONG3,332,843$484.8 million

WAT

WATERS CORP

LONG1,256,462$374.2 million

CARNIVAL CORP

CARNIVAL CORP

LONG13,721,348$355.1 million

HAS

HASBRO INC

LONG3,738,902$350.0 million

RDDT

REDDIT INC

LONG2,551,617$343.6 million

AIG

AMERICAN INTL GROUP INC

LONG4,221,223$317.6 million

CBOE

CBOE GLOBAL MKTS INC

LONG688,417$193.5 million

HD

HOME DEPOT INC

LONG504,257$165.8 million

LULU

LULULEMON ATHLETICA INC

LONG980,568$150.1 million

CRWV

COREWEAVE INC

LONG1,397,438$108.3 million

VERADERMICS INC

VERADERMICS INC

LONG1,690,555$106.8 million

INTERACTIVE BROKERS GROUP IN

INTERACTIVE BROKERS GROUP IN

LONG1,394,329$93.5 million

EW

EDWARDS LIFESCIENCES CORP

LONG1,097,578$87.9 million

DAMORA THERAPEUTICS INC

DAMORA THERAPEUTICS INC

LONG2,311,082$59.9 million

TWLO

TWILIO INC

LONG450,770$56.7 million

EQPT

EQUIPMENTSHARE COM INC

LONG1,000,000$20.4 million

FORGENT POWER SOLUTIONS INC

FORGENT POWER SOLUTIONS INC

LONG650,000$19.0 million

RALLYBIO CORP

RALLYBIO CORP

LONG524,347$4.7 million

No longer reported this quarter

Present in the prior comparable filing and absent from this one.

PositionKindPrior sharesPrior value

AMD

ADVANCED MICRO DEVICES INC · COM

LONG3,742,191$801.4 million

BANK AMERICA CORP

BANK AMERICA CORP · COM

LONG4,494,629$247.2 million

BOSTON SCIENTIFIC CORP

BOSTON SCIENTIFIC CORP · COM

LONG2,509,808$239.3 million

CARNIVAL CORP

CARNIVAL CORP · UNIT 99/99/9999

LONG14,061,827$429.4 million

CHEWY INC

CHEWY INC · CL A

LONG13,536,645$447.4 million

COSTAR GROUP INC

COSTAR GROUP INC · COM

LONG1,442,582$97.0 million

DIGITAL RLTY TR INC

DIGITAL RLTY TR INC · COM

LONG1,507,988$233.3 million

DRAFTKINGS INC NEW

DRAFTKINGS INC NEW · COM CL A

LONG19,119,912$658.9 million

FIGMA INC

FIGMA INC · CLASS A COM STK

LONG5,752,388$215.0 million

IQVIA HLDGS INC

IQVIA HLDGS INC · COM

LONG619,236$139.6 million

ITAU UNIBANCO HLDG S A

ITAU UNIBANCO HLDG S A · SPON ADR REP PFD

LONG28,396,545$203.3 million

LOWES COS INC

LOWES COS INC · COM

LONG912,040$219.9 million

MASIMO CORP

MASIMO CORP · COM

LONG514,340$66.9 million

RALLYBIO CORP

RALLYBIO CORP · COM

LONG4,194,777$2.9 million

RIOT

RIOT PLATFORMS INC · COM

LONG12,428,894$157.5 million

ROSS STORES INC

ROSS STORES INC · COM

LONG3,167,479$570.6 million

SAIA INC

SAIA INC · COM

LONG1,088,582$355.4 million

TRADEWEB MKTS INC

TRADEWEB MKTS INC · CL A

LONG2,768,659$297.7 million

UBS GROUP AG

UBS GROUP AG · SHS

LONG9,128,817$426.0 million

UNITEDHEALTH GROUP INC

UNITEDHEALTH GROUP INC · COM

LONG1,197,273$395.2 million

“No longer reported” means the position is absent from this comparable 13F filing. It does not prove the manager sold it: reporting thresholds, confidential treatment, corporate actions, or instrument changes can also explain the omission.

PositionKindSharesValueLong weightQuarter changeAI at filing · 1YAI now

V

Visa Inc.

LONG6,328,185$1.91 billion5.5%INCREASED—

1Y —

5Y —

TSM

Taiwan Semiconductor Manufacturing Co.

LONG4,465,127$1.51 billion4.3%REDUCED24.7%

1Y +23.6%

5Y +129.0% · 5 models

SCHW

Charles Schwab Corporation

LONG14,664,954$1.38 billion3.9%INCREASED17.1%

1Y +17.4%

5Y +83.4% · 5 models

DIS

Walt Disney Co.

LONG13,298,462$1.28 billion3.7%INCREASED15.2%

1Y +13.7%

5Y +65.8% · 6 models

FTV

Fortive

LONG22,479,388$1.24 billion3.6%INCREASED—

1Y —

5Y —

AIR PRODUCTS AND CHEMICALS I

AIR PRODUCTS AND CHEMICALS I · COM · 009158106

LONG4,104,095$1.19 billion3.4%REDUCED—

1Y —

5Y —

MCD

McDonald's Corp.

LONG3,625,029$1.13 billion3.2%INCREASED10.1%

1Y +9.3%

5Y +54.4% · 5 models

SHW

Sherwin-Williams

LONG3,112,767$997.8 million2.9%REDUCED—

1Y —

5Y —

TSLA

Tesla Inc.

LONG2,493,561$927.0 million2.7%INCREASED23.9%

1Y +6.2%

5Y +98.3% · 6 models

APPLE INC

APPLE INC · COM · 037833100

LONG3,593,057$911.9 million2.6%NEWLY REPORTED—

1Y —

5Y —

BRIDGEBIO PHARMA INC

BRIDGEBIO PHARMA INC · COM · 10806X102

LONG11,842,434$879.4 million2.5%REDUCED—

1Y —

5Y —

CVNA

CARVANA CO · CL A · 146869102

LONG2,780,035$874.0 million2.5%INCREASED—

1Y —

5Y —

MSFT

Microsoft Corporation

LONG2,309,446$854.9 million2.4%REDUCED17.4%

1Y +15.3%

5Y +90.8% · 6 models

TMO

Thermo Fisher Scientific Inc.

LONG1,668,025$819.9 million2.3%INCREASED12.5%

1Y +12.1%

5Y +69.0% · 5 models

JPM

JPMorgan Chase & Co.

LONG2,704,018$795.4 million2.3%INCREASED13.4%

1Y +11.0%

5Y +64.7% · 6 models

CSX

CSX Corporation

LONG18,678,052$766.7 million2.2%INCREASED—

1Y —

5Y —

ICE

Intercontinental Exchange

LONG4,836,896$760.7 million2.2%INCREASED—

1Y —

5Y —

LENNOX INTL INC

LENNOX INTL INC · COM · 526107107

LONG1,572,419$729.8 million2.1%INCREASED—

1Y —

5Y —

GOOGL

ALPHABET INC · CAP STK CL A · 02079K305

LONG2,395,865$689.0 million2.0%REDUCED—

1Y +15.8%

5Y +98.3% · 6 models

FDX

FedEx

LONG1,932,165$688.2 million2.0%NEWLY REPORTED—

1Y —

5Y —

GM

General Motors

LONG9,176,943$683.7 million2.0%INCREASED—

1Y —

5Y —

BA

Boeing Co.

LONG3,196,041$636.1 million1.8%REDUCED20.1%

1Y +16.5%

5Y +72.5% · 6 models

PNC

PNC Financial Services Group Inc.

LONG3,027,092$629.9 million1.8%REDUCED12.3%

1Y +12.0%

5Y +57.6% · 5 models

TMUS

T-Mobile US

LONG2,967,374$623.2 million1.8%REDUCED—

1Y —

5Y —

META

Meta Platforms Inc.

LONG1,062,575$607.9 million1.7%NEWLY REPORTED23.7%

1Y +19.2%

5Y +116.7% · 6 models

REGAL REXNORD CORPORATION

REGAL REXNORD CORPORATION · COM · 758750103

LONG3,142,851$588.5 million1.7%REDUCED—

1Y —

5Y —

MAA

Mid-America Apartments

LONG4,798,404$586.0 million1.7%INCREASED—

1Y —

5Y —

JCI

Johnson Controls

LONG4,419,923$578.8 million1.7%REDUCED—

1Y —

5Y —

MEDLINE INC

MEDLINE INC · COM CL A · 58507V107

LONG11,433,992$508.8 million1.5%INCREASED—

1Y —

5Y —

HCA

HCA Healthcare

LONG1,075,133$508.8 million1.5%INCREASED—

1Y —

5Y —

ATI INC

ATI INC · COM · 01741R102

LONG3,332,843$484.8 million1.4%NEWLY REPORTED—

1Y —

5Y —

CLS

Celestica Inc.

LONG1,654,989$466.2 million1.3%REDUCED29.2%

1Y +26.2%

5Y +132.0% · 5 models

CAMDEN PPTY TR

CAMDEN PPTY TR · SH BEN INT · 133131102

LONG4,715,394$460.5 million—REDUCED—

1Y —

5Y —

CHUBB LTD SWITZ

CHUBB LTD SWITZ · COM · H1467J104

LONG1,295,011$422.1 million1.2%INCREASED—

1Y —

5Y —

ADAPTIVE BIOTECHNOLOGIES COR

ADAPTIVE BIOTECHNOLOGIES COR · COM · 00650F109

LONG29,993,708$416.3 million1.2%UNCHANGED—

1Y —

5Y —

BIOMARIN PHARMACEUTICAL INC

BIOMARIN PHARMACEUTICAL INC · COM · 09061G101

LONG7,062,077$398.9 million1.1%INCREASED—

1Y —

5Y —

SEA LTD

SEA LTD · SPONSORD ADS · 81141R100

LONG4,737,196$392.3 million—INCREASED—

1Y —

5Y —

WAT

Waters Corporation

LONG1,256,462$374.2 million1.1%NEWLY REPORTED11.8%

1Y +9.6%

5Y +55.0% · 5 models

CARNIVAL CORP

CARNIVAL CORP · COMMON STOCK · 143658300

LONG13,721,348$355.1 million1.0%NEWLY REPORTED—

1Y —

5Y —

AON

Aon plc

LONG1,087,114$350.9 million1.0%INCREASED—

1Y —

5Y —

HAS

Hasbro

LONG3,738,902$350.0 million1.0%NEWLY REPORTED—

1Y —

5Y —

RDDT

Reddit Inc.

LONG2,551,617$343.6 million1.0%NEWLY REPORTED30.5%

1Y +24.6%

5Y +150.0% · 5 models

PGR

Progressive Corporation

LONG1,616,559$320.5 million0.9%INCREASED—

1Y —

5Y —

AIG

American International Group

LONG4,221,223$317.6 million0.9%NEWLY REPORTED—

1Y —

5Y —

CAPITAL ONE FINL CORP

CAPITAL ONE FINL CORP · COM · 14040H105

LONG1,612,374$294.1 million0.8%REDUCED—

1Y —

5Y —

DKS

DICKS SPORTING GOODS INC · COM · 253393102

LONG1,264,170$250.7 million0.7%REDUCED—

1Y —

5Y —

AMZN

AMAZON COM INC · COM · 023135106

LONG1,195,428$249.0 million0.7%REDUCED—

1Y +19.2%

5Y +115.8% · 6 models

AMER SPORTS INC

AMER SPORTS INC · COM SHS · G0260P102

LONG7,270,476$239.3 million0.7%INCREASED—

1Y —

5Y —

APG

APi Group Corporation

LONG5,837,000$236.5 million0.7%REDUCED19.0%

1Y +17.4%

5Y +90.0% · 5 models

TIC SOLUTIONS INC

TIC SOLUTIONS INC · COM · 00510N102

LONG35,824,562$235.7 million0.7%INCREASED—

1Y —

5Y —

CBOE

Cboe Global Markets

LONG688,417$193.5 million0.6%NEWLY REPORTED—

1Y —

5Y —

ROIV

Roivant Sciences Ltd

LONG6,652,448$184.3 million0.5%INCREASED34.2%

1Y +26.0%

5Y +121.7% · 6 models

HD

Home Depot Inc.

LONG504,257$165.8 million0.5%NEWLY REPORTED10.5%

1Y +9.6%

5Y +59.0% · 5 models

AJG

Arthur J. Gallagher & Co.

LONG727,441$157.5 million0.5%REDUCED—

1Y —

5Y —

LULU

Lululemon Athletica Inc.

LONG980,568$150.1 million0.4%NEWLY REPORTED15.7%

1Y +4.2%

5Y +70.0% · 5 models

NEWAMSTERDAM PHARMA COMPANY

NEWAMSTERDAM PHARMA COMPANY · ORDINARY SHARES · N62509109

LONG4,203,567$134.6 million0.4%UNCHANGED—

1Y —

5Y —

ORUKA THERAPEUTICS INC

ORUKA THERAPEUTICS INC · COM · 687604108

LONG2,666,690$130.8 million0.4%UNCHANGED—

1Y —

5Y —

SIONNA THERAPEUTICS INC

SIONNA THERAPEUTICS INC · COM · 829401108

LONG3,195,181$128.1 million0.4%UNCHANGED—

1Y —

5Y —

STELLANTIS N.V

STELLANTIS N.V · SHS · N82405106

LONG15,980,268$111.9 million0.3%REDUCED—

1Y —

5Y —

CRWV

CoreWeave Inc

LONG1,397,438$108.3 million0.3%NEWLY REPORTED50.6%

1Y +24.6%

5Y +141.0% · 5 models

VERADERMICS INC

VERADERMICS INC · COMMON STOCK · 922967104

LONG1,690,555$106.8 million0.3%NEWLY REPORTED—

1Y —

5Y —

WST

West Pharmaceutical Services

LONG416,948$104.5 million0.3%INCREASED—

1Y —

5Y —

PHARVARIS N V

PHARVARIS N V · COM · N69605108

LONG3,653,310$103.2 million0.3%UNCHANGED—

1Y —

5Y —

INHIBRX BIOSCIENCES INC

INHIBRX BIOSCIENCES INC · COM · 45720N103

LONG1,437,705$96.7 million0.3%UNCHANGED—

1Y —

5Y —

INTERACTIVE BROKERS GROUP IN

INTERACTIVE BROKERS GROUP IN · COM CL A · 45841N107

LONG1,394,329$93.5 million0.3%NEWLY REPORTED—

1Y —

5Y —

RALLIANT CORP

RALLIANT CORP · COM · 750940108

LONG2,134,899$88.8 million0.3%REDUCED—

1Y —

5Y —

EW

Edwards Lifesciences

LONG1,097,578$87.9 million0.3%NEWLY REPORTED—

1Y —

5Y —

ORIC PHARMACEUTICALS INC

ORIC PHARMACEUTICALS INC · COM · 68622P109

LONG5,824,533$73.8 million0.2%REDUCED—

1Y —

5Y —

DAMORA THERAPEUTICS INC

DAMORA THERAPEUTICS INC · COM NEW · 36322Q206

LONG2,311,082$59.9 million0.2%NEWLY REPORTED—

1Y —

5Y —

TWLO

Twilio Inc.

LONG450,770$56.7 million0.2%NEWLY REPORTED21.9%

1Y +18.8%

5Y +105.0% · 5 models

STANDARD BIOTOOLS INC

STANDARD BIOTOOLS INC · COM · 34385P108

LONG58,651,170$53.9 million0.2%UNCHANGED—

1Y —

5Y —

TREVI THERAPEUTICS INC

TREVI THERAPEUTICS INC · COM · 89532M101

LONG3,198,644$38.2 million0.1%UNCHANGED—

1Y —

5Y —

GINKGO BIOWORKS HOLDINGS INC

GINKGO BIOWORKS HOLDINGS INC · CL A NEW · 37611X209

LONG3,577,128$21.9 million0.1%UNCHANGED—

1Y —

5Y —

EQPT

EQUIPMENTSHARE COM INC · COM CL A · 29445S100

LONG1,000,000$20.4 million0.1%NEWLY REPORTED—

1Y —

5Y —

FORGENT POWER SOLUTIONS INC

FORGENT POWER SOLUTIONS INC · COM SHS CL A · 34631F102

LONG650,000$19.0 million0.1%NEWLY REPORTED—

1Y —

5Y —

PEPGEN INC

PEPGEN INC · COM · 713317105

LONG3,482,434$6.2 million0.0%UNCHANGED—

1Y —

5Y —

RALLYBIO CORP

RALLYBIO CORP · COM · 75120L209

LONG524,347$4.7 million0.0%NEWLY REPORTED—

1Y —

5Y —

AI outlook values are averages across the latest successful run per covered model at the labeled cutoff. “No longer reported” does not necessarily mean sold; thresholds, confidential treatment, corporate actions, or instrument changes may explain an omission. Reviewed API mapping covers 68.4%of disclosed long-book value; exact editorial CUSIP mappings may add current-only AI coverage on this public page. Research use only. No warranty and not investment advice.

Filing history

Get filing alerts →

Every filing event remains separate, including notices and amendments. Open a holdings date for the canonical portfolio through its latest filing, or an accession for the exact source event.

Holdings dateFiledFormProcessingAccession
2026-03-312026-05-1513F-HRVALIDATED0001103804-26-000004
2025-12-312026-02-1713F-HRVALIDATED0001103804-26-000002
2025-09-302025-11-1413F-HRVALIDATED0001103804-25-000010
2025-06-302025-08-1413F-HRVALIDATED0001103804-25-000007
2025-03-312025-05-1513F-HRVALIDATED0001103804-25-000004
2024-12-312025-02-1413F-HRVALIDATED0001103804-25-000002
2024-09-302024-11-1413F-HRVALIDATED0001103804-24-000006
2024-06-302024-08-1413F-HRVALIDATED0000905148-24-002226
2024-03-312024-05-1513F-HRVALIDATED0001103804-24-000004
2023-12-312024-02-1413F-HRVALIDATED0001103804-24-000002
2023-09-302023-11-1413F-HRVALIDATED0001103804-23-000009
2023-06-302023-08-1413F-HRVALIDATED0001103804-23-000006
2023-03-312023-05-1513F-HRVALIDATED0001103804-23-000004
2022-12-312023-02-1413F-HRVALIDATED0001103804-23-000002
2022-09-302022-11-1413F-HRVALIDATED0001103804-22-000006
2022-06-302022-08-1513F-HRVALIDATED0001103804-22-000004
2021-12-312022-05-1613F-HR/A · restatementVALIDATED0001567619-22-010954
2021-09-302022-05-1613F-HR/A · restatementVALIDATED0001567619-22-010950
2022-03-312022-05-1613F-HRVALIDATED0001103804-22-000003
2021-12-312022-02-1413F-HRVALIDATED0001103804-22-000002
2021-09-302021-11-1513F-HRVALIDATED0001103804-21-000009
2021-06-302021-08-1613F-HRVALIDATED0001103804-21-000006
2021-03-312021-05-1713F-HRVALIDATED0001103804-21-000004
2020-12-312021-02-1613F-HRVALIDATED0001103804-21-000003
2020-09-302020-11-1613F-HRVALIDATED0001103804-20-000009
2020-06-302020-08-0713F-HRVALIDATED0001103804-20-000007
2020-03-312020-05-1313F-HRVALIDATED0001103804-20-000005
2019-12-312020-02-1313F-HRVALIDATED0001103804-20-000003
2019-09-302019-11-1313F-HRVALIDATED0001103804-19-000014
2019-06-302019-08-1413F-HRVALIDATED0001103804-19-000011
2019-03-312019-05-1513F-HRVALIDATED0001103804-19-000006
2018-12-312019-02-1413F-HRVALIDATED0001103804-19-000002
2018-09-302018-11-1413F-HRVALIDATED0001103804-18-000045
2018-06-302018-08-1413F-HRVALIDATED0001103804-18-000039
2018-03-312018-05-1513F-HRVALIDATED0001103804-18-000031
2017-12-312018-02-1413F-HRVALIDATED0001103804-18-000004
2017-09-302017-11-1413F-HRVALIDATED0001103804-17-000061
2017-06-302017-08-1413F-HRVALIDATED0001103804-17-000049
2017-03-312017-05-1513F-HRVALIDATED0001103804-17-000040
2016-12-312017-02-1413F-HRVALIDATED0001103804-17-000034
2016-09-302016-11-1413F-HRVALIDATED0001103804-16-000126
2016-06-302016-08-1513F-HRVALIDATED0001103804-16-000123
2016-03-312016-05-1613F-HRVALIDATED0001103804-16-000116
2015-12-312016-02-1613F-HRVALIDATED0001103804-16-000077
2015-09-302015-11-1613F-HRVALIDATED0001103804-15-000061
2015-06-302015-08-1413F-HRVALIDATED0001103804-15-000048
2015-03-312015-05-1513F-HRVALIDATED0001103804-15-000034
2014-12-312015-02-1713F-HRVALIDATED0001103804-15-000015
2014-09-302014-11-1413F-HRVALIDATED0001103804-14-000044
2014-06-302014-08-1413F-HRVALIDATED0001103804-14-000036
2014-03-312014-05-1513F-HRVALIDATED0001103804-14-000027
2013-12-312014-02-1413F-HRVALIDATED0000902664-14-001132
2013-09-302013-11-1413F-HRVALIDATED0000902664-13-003741
2013-06-302013-08-1413F-HRVALIDATED0000902664-13-002950
2013-03-312013-05-1413F-HRVALIDATED0001103804-13-000022
2012-12-312013-02-1413F-HRVALIDATED0001103804-13-000004
2012-09-302012-11-1413F-HRVALIDATED0001103804-12-000035
2012-06-302012-08-1413F-HRVALIDATED0001103804-12-000030
2012-03-312012-05-1513F-HRVALIDATED0001103804-12-000027
2011-12-312012-02-1413F-HRVALIDATED0001103804-12-000022
2011-09-302011-11-1413F-HRVALIDATED0001103804-11-000041
2011-06-302011-08-1513F-HRVALIDATED0001103804-11-000037
2011-03-312011-05-1613F-HRVALIDATED0001103804-11-000033
2010-12-312011-02-1113F-HRQUARANTINED0001103804-11-000023
2010-09-302010-11-1513F-HRQUARANTINED0000902664-10-003592
2010-06-302010-08-1613F-HRQUARANTINED0001103804-10-000011
2010-03-312010-05-1713F-HRQUARANTINED0001103804-10-000005
2009-12-312010-02-1613F-HRQUARANTINED0001103804-10-000003
2009-09-302009-11-1613F-HRQUARANTINED0001103804-09-000014
2009-06-302009-08-1713F-HR/A · add new holdingsVALIDATED0001103804-09-000011
2009-06-302009-08-1413F-HRVALIDATED0001103804-09-000008
2009-03-312009-05-1513F-HRVALIDATED0001103804-09-000005
2008-12-312009-02-1713F-HRVALIDATED0001103804-09-000002
2008-09-302008-11-1413F-HRQUARANTINED0001103804-08-000016
2008-06-302008-08-1413F-HRVALIDATED0001103804-08-000013
2008-03-312008-05-1513F-HRQUARANTINED0001103804-08-000010
2007-12-312008-02-1913F-HR/A · restatementVALIDATED0001103804-08-000007
2007-12-312008-02-1413F-HRVALIDATED0001103804-08-000006
2007-09-302007-11-1413F-HRVALIDATED0001103804-07-000013
2007-06-302007-08-1413F-HRVALIDATED0001103804-07-000010
2007-03-312007-05-1513F-HRVALIDATED0001103804-07-000007
2006-12-312007-02-1413F-HRVALIDATED0001103804-07-000002
2006-09-302006-11-1413F-HRQUARANTINED0001103804-06-000018
2006-06-302006-08-1413F-HRVALIDATED0001103804-06-000016
2006-03-312006-05-1513F-HRVALIDATED0001103804-06-000013
2005-12-312006-02-1413F-HRVALIDATED0001103804-06-000005
2005-09-302005-11-1413F-HRVALIDATED0001103804-05-000019
2005-06-302005-08-1513F-HRVALIDATED0001103804-05-000013
2005-03-312005-05-1613F-HRVALIDATED0001103804-05-000011
2004-12-312005-02-1513F-HRVALIDATED0001103804-05-000006
2004-09-302004-11-1513F-HRVALIDATED0001103804-04-000016
2004-06-302004-08-1613F-HRVALIDATED0001103804-04-000013
2004-03-312004-05-1413F-HRQUARANTINED0001103804-04-000008
2003-12-312004-02-1313F-HRVALIDATED0001103804-04-000004
2003-09-302003-11-1413F-HRVALIDATED0001103804-03-000034
2003-06-302003-08-1813F-HR/A · restatementVALIDATED0001103804-03-000031
2003-06-302003-08-1813F-HRQUARANTINED0001103804-03-000026
2003-03-312003-05-2113F-HR/A · restatementVALIDATED0001103804-03-000015
2003-03-312003-05-1513F-HRVALIDATED0001103804-03-000008
2002-12-312003-02-1113F-HRVALIDATED0001103804-03-000004
2001-03-312001-05-1513F-HRQUARANTINED0000728672-01-500047
2000-12-292001-02-1313F-HRQUARANTINED0000728672-01-000027
2000-09-292000-11-1313F-HRQUARANTINED0000728672-00-000186
2000-06-302000-08-1113F-HRQUARANTINED0000728672-00-000122
Open interactive changes in the app